Genetic Analysis Links Addiction Risk to Reward, Impulse, and Externalizing Pathways

Key Takeaways:

• A new analysis was separated a broad externalizing genetic liability from substance-specific genetic signals across substance use disorders and related traits.
• Broad-liability loci mapped to brain signaling, reward, and neural plasticity systems, while substance-specific loci were reported in pathways such as alcohol metabolism and nicotinic receptor biology.
• Polygenic-score findings were reported to differ by scope (broad versus substance-specific).

The investigators aggregated previously published genome-wide association datasets and analyzed genetic data drawn from more than 2.2 million individuals. Their approach combined substance use disorders with related externalizing traits in a multivariate modeling framework to partition genetic effects into shared versus substance-specific components. The report notes that modeling these conditions together was intended to increase detection of genetic effects while preserving the ability to differentiate signals tied more closely to particular substances.

When associated loci were mapped to biological systems, broad-liability signals were localized to genes involved in brain signaling, reward processing, and neural plasticity. By contrast, substance-specific loci mapped to pathways tied to particular drugs, including alcohol metabolism enzymes and nicotinic acetylcholine receptors implicated in tobacco use.

Broad externalizing polygenic scores were predictive across multiple substance use disorders, while substance-specific scores are presented as adding more precise information about vulnerability to particular drugs. Network and drug-target analyses pointed to potential biological systems and medications that might be considered for future study or repurposing.

The authors note that the analyses were limited to individuals of European ancestry, reflecting the availability of large-scale datasets.